TIMI Risk Score for UA/NSTEMI

Advancing age is a fundamental risk factor for adverse outcomes across all acute coronary syndromes. Older patients have greater comorbidity burdens, reduced cardiac reserve, higher prevalence of multi-vessel disease, and increased susceptibility to complications from both the disease and its treatment (bleeding, renal impairment, procedural complications).

The binary threshold of 65 years captures the inflection point where ACS event rates begin to rise sharply. Patients just under 65 with significant comorbidities may still be at elevated risk not captured by this criterion alone — clinical judgement should always complement the score.

This criterion evaluates the burden of traditional modifiable risk factors for coronary artery disease. Specifically, 3 or more of the following five must be present to score 1 point:

• Family history of premature CAD — first-degree relative with CAD before age 55 (male) or 65 (female)
• Hypertension — current diagnosis or on antihypertensive therapy
• Hypercholesterolaemia — known diagnosis or on lipid-lowering therapy
• Diabetes mellitus — type 1 or type 2
• Current active smoker — active tobacco use at the time of presentation

A high risk factor burden indicates diffuse atherosclerotic disease and a greater likelihood that the acute presentation reflects a vulnerable plaque in the context of widespread coronary pathology.

This criterion is positive if the patient has prior angiographic documentation of ≥ 50% stenosis in any epicardial coronary artery. It can also be inferred from a history of prior myocardial infarction, prior PCI (stent placement), prior CABG, or documented obstructive coronary disease on CT coronary angiography.

Known CAD indicates that the acute presentation is occurring against a background of established coronary atherosclerosis, which carries higher risk than a de novo presentation in a patient without known disease. It also suggests that the patient may have already exhausted some revascularisation options or may have complex coronary anatomy.

This is often the most counterintuitive criterion for trainees — aspirin is protective, so why does its use add a point? The rationale is that a patient who develops an acute coronary event despite taking aspirin has experienced a “breakthrough” event. This suggests more aggressive underlying disease that is not adequately controlled by first-line antiplatelet prophylaxis.

In the derivation cohort, aspirin use in the preceding 7 days was independently associated with higher 14-day event rates, likely because it serves as a marker for patients with known cardiovascular disease who are already on secondary prevention therapy yet still developed acute ischaemia.

Two or more episodes of anginal chest pain within 24 hours of presentation indicates an accelerating or crescendo pattern of ischaemia. This pattern suggests an unstable plaque with ongoing intermittent flow limitation — a higher-risk pathophysiology than a single isolated episode.

The recurrence of symptoms despite initial management (rest, sublingual nitroglycerin) further suggests that the ischaemic substrate is actively evolving and may progress to complete occlusion or infarction without intervention. This criterion captures the clinical instability component of the presentation.

ST-segment depression of ≥ 0.5 mm (0.05 mV) on the presenting ECG is an objective marker of subendocardial ischaemia. Transient ST elevation that resolves can also qualify if it represents dynamic ischaemia (as opposed to persistent ST elevation, which would classify the patient as STEMI).

ECG changes provide real-time evidence of myocardial ischaemia and are among the strongest individual predictors of adverse outcomes in NSTE-ACS. The depth and distribution of ST depression correlate with the extent and severity of ischaemia. Patients with widespread ST depression (≥ 6 leads) or depression ≥ 2 mm are at particularly high risk and may warrant very early invasive evaluation.

Elevated cardiac biomarkers — cardiac troponin I (cTnI), cardiac troponin T (cTnT), or CK-MB — above the institutional 99th percentile upper reference limit indicate myocardial necrosis. This criterion distinguishes NSTEMI from unstable angina and is the single most prognostically important variable in the score.

With high-sensitivity troponin assays now standard in most institutions, even small elevations carry prognostic significance. A rising or falling pattern on serial measurement is more specific for acute MI than a single elevated value, which may reflect chronic myocardial injury (e.g., in heart failure or renal impairment). For TIMI scoring purposes, any elevation above the institutional normal threshold qualifies.

Patients with positive biomarkers consistently derive the greatest benefit from early invasive strategies and potent antithrombotic therapy (GP IIb/IIIa inhibitors, P2Y12 inhibitors).

The Global Registry of Acute Coronary Events (GRACE) score is a more complex model derived from a large multinational registry of ACS patients. It predicts in-hospital mortality and 6-month post-discharge mortality using 8 variables: age, heart rate, systolic BP, creatinine, Killip class, cardiac arrest at presentation, ST-segment deviation, and elevated cardiac markers. It requires a dedicated calculator or nomogram for computation.

The GRACE score generally provides superior discrimination compared to TIMI (c-statistic ~0.83 vs ~0.65 for TIMI in some validation studies), particularly for mortality prediction. Current ESC guidelines preferentially recommend GRACE for NSTE-ACS risk stratification. However, the TIMI score’s simplicity and its direct linkage to interventional trial data (TACTICS-TIMI 18) make it a valuable complementary tool, especially in resource-limited settings or for rapid bedside assessment.

The HEART score was designed for a different clinical scenario: undifferentiated chest pain in the emergency department where ACS has not yet been confirmed or excluded. The TIMI UA/NSTEMI score, by contrast, is intended for patients in whom UA/NSTEMI is already the working diagnosis. The HEART score helps decide whether a patient can be safely discharged from the ED; the TIMI score helps decide the intensity of treatment once ACS is established.

Using the TIMI UA/NSTEMI score for undifferentiated chest pain (where many patients will not have ACS at all) is inappropriate and may lead to incorrect risk estimation. Conversely, using the HEART score for a patient with confirmed NSTEMI is not its intended purpose.

The TIMI STEMI score is a completely separate tool. The critical differences are:

• Population: UA/NSTEMI score is for non-ST-elevation ACS; STEMI score is for confirmed ST-elevation MI
• Variables: UA/NSTEMI uses 7 binary criteria (each = 1 point); STEMI uses 8 weighted criteria (points range from 1 to 3)
• Range: UA/NSTEMI = 0–7; STEMI = 0–14
• Endpoint: UA/NSTEMI predicts 14-day death/MI/urgent revascularisation; STEMI predicts 30-day all-cause mortality
• Derivation: UA/NSTEMI from TIMI 11B; STEMI from InTIME II

These two scores should never be confused or interchanged. Always confirm which TIMI score is being used in clinical documentation and handoffs.